Short Interest Coverage: What’s Vericel Corporation (NASDAQ:VCEL) Upside After This Short Interest Increase?

November 18, 2016 - By Winifred Garcia   ·   0 Comments

Short Interest Coverage: What's Vericel Corporation (NASDAQ:VCEL) Upside After This Short Interest Increase?

The stock of Vericel Corporation (NASDAQ:VCEL) registered an increase of 18.58% in short interest. VCEL’s total short interest was 187,000 shares in November as published by FINRA. Its up 18.58% from 157,700 shares, reported previously. With 113,700 shares average volume, it will take short sellers 2 days to cover their VCEL’s short positions. The short interest to Vericel Corporation’s float is 1.09%. About 259,869 shares traded hands. Vericel Corp (NASDAQ:VCEL) has declined 30.84% since April 18, 2016 and is downtrending. It has underperformed by 35.27% the S&P500.

Vericel Corporation, formerly Aastrom Biosciences, Inc., is a commercial-stage biopharmaceutical firm dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The company has a market cap of $56.09 million. The Firm operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment. It currently has negative earnings. The Company’s autologous cell therapy products include Carticel , which is an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel (cultured epidermal autografts), which is a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns.

Vericel Corp (NASDAQ:VCEL) Ratings Coverage

Out of 2 analysts covering Vericel (NASDAQ:VCEL), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. Vericel has been the topic of 3 analyst reports since March 11, 2016 according to StockzIntelligence Inc. Bank of America downgraded the stock to “Neutral” rating in Tuesday, April 5 report. The firm has “Buy” rating given on Wednesday, November 9 by Needham. On Friday, March 11 the stock rating was upgraded by Needham to “Buy”.

VCEL Company Profile

Vericel Corporation (Vericel), formerly Aastrom Biosciences, Inc., incorporated on March 24, 1989, is a commercial-stage biopharmaceutical firm dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Firm operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment. Vericel markets two autologous cell therapy products in the United States: Carticel (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns approximately 30% of total body surface area (TBSA).

More news for Vericel Corp (NASDAQ:VCEL) were recently published by: Marketwatch.com, which released: “Vericel Corp. NASDAQ: VCEL” on November 28, 2014. Quotes.Wsj.com‘s article titled: “News Vericel Corp.VCEL” and published on November 27, 2014 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Winifred Garcia


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>